


SSTR5 antagonist 2 TFA

Cat. No.:	HY-114191A
CAS No.:	1254733-98-6
Molecular Formula:	C ₃₄ H ₃₆ F ₄ N ₂ O ₇
Molecular Weight:	660.65
Target:	Somatostatin Receptor
Pathway:	GPCR/G Protein; Neuronal Signaling
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	SSTR5 Antagonist 1 (compound 10) is a highly potent, oral active and selective somatostatin (receptor) subtype 5 (SSTR5) antagonist and has potential for the research of treat type 2 diabetes mellitus (T2DM) ^[1] .								
IC₅₀ & Target	SSTR5 ^[1] .								
In Vivo	<p>SSTR5 antagonist 2 (10 mg/kg, orally) increases both total and active circulating incretin hormone GLP1 levels in mice at a dose of 10 mg/kg^[1].</p> <p>SSTR5 antagonist 2 increases pancreatic insulin secretion as well as total and active GLP1 release, and demonstrates synergistic effects in combination with DPP4 inhibitors^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Rodent diabetic model without risk of hypoglycemia^[1].</td> </tr> <tr> <td>Dosage:</td> <td>10 mg/kg.</td> </tr> <tr> <td>Administration:</td> <td>Orally.</td> </tr> <tr> <td>Result:</td> <td>Increased both total and active circulating incretin hormone GLP1 levels.</td> </tr> </table>	Animal Model:	Rodent diabetic model without risk of hypoglycemia ^[1] .	Dosage:	10 mg/kg.	Administration:	Orally.	Result:	Increased both total and active circulating incretin hormone GLP1 levels.
Animal Model:	Rodent diabetic model without risk of hypoglycemia ^[1] .								
Dosage:	10 mg/kg.								
Administration:	Orally.								
Result:	Increased both total and active circulating incretin hormone GLP1 levels.								

REFERENCES

[1]. Liu W, et al. Discovery and Pharmacology of a Novel Somatostatin Subtype 5 (SSTR5) Antagonist: Synergy with DPP-4 Inhibition. ACS Med Chem Lett. 2018 Sep 12;9(11):1082-1087.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA